Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Wedbush from $67.00 to $57.00 in a report issued on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q1 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s share price fell 3.3% during mid-day trading on Monday . The stock traded as low as $54.07 and last traded at $54.07. 120,819 shares were traded during trading, a decline of 92% from the average session volume of 1,495,266 shares. The stock had previously closed at $55.91. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]
Victory Capital Management Inc. grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 84.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 738,511 shares of the company’s stock after purchasing an additional 337,554 shares during the period. Victory Capital Management Inc. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price boosted by stock analysts at Oppenheimer from $75.00 to $79.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 20.78% from the […]